Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc is poised for growth as it raises its FY26 EPS estimates, reflecting a more favorable financial outlook due to a higher share count. The anticipated approval of the MyoVista device, alongside the rollout of the MyoVista Insights cloud platform and a likely FDA approval of its first diagnostic algorithm by the first half of 2026, underscores significant market potential. The company's strategic positioning and technological advancements paint a promising picture for its future in the medical technology sector.

Bears say

HeartSciences Inc. faces significant challenges that contribute to a negative outlook on its stock, largely stemming from substantial FDA-related delays that have resulted in a drastic reduction of its FY2026 revenue estimate from $1.2 million to only $0.1 million. Additionally, the company is confronted with various risks, including balance sheet and liquidity issues, potential failures in product safety and efficacy during clinical trials, and difficulties in achieving necessary regulatory approvals and commercial viability for its product offerings. Furthermore, external factors such as competitive pressures, evolving macroeconomic conditions, and shifting investor sentiment in the healthcare sector may exacerbate the challenges faced by HeartSciences, undermining its growth prospects.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.